Twenty million USD has been funneled into clinical trials of a vaccination method which does not need a needle. The recipient is biotech company “Vaxxas”.

This is the second round of funding which will be used to further research and develop the patented Nanopatch by Vaxxas, which has already raised a total capital of 31.48 million dollars.

The system is aiming at providing a vaccination technique which does not require a needle. The Nanopatch is exactly what its name suggets: A patch which targets cells right under the skin. Vaxxas is trying to develop vaccines for a number of serious illnesses, such as the flu, polio, bacterial infections, and cancer.

The technology was developed by a research team led by Mark Kendall of the Institute for Bioengineering and Nanotechnology in Australia’s Queensland University. The Nanopatch does not need to be refrigerated during transfer, storage or transportation, which is a huge advantage of applying it to vaccination needs, especially in the developing world.